153 related articles for article (PubMed ID: 26277432)
1. In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio.
Gani C; Coackley C; Kumareswaran R; Schütze C; Krause M; Zafarana G; Bristow RG
Radiother Oncol; 2015 Sep; 116(3):486-94. PubMed ID: 26277432
[TBL] [Abstract][Full Text] [Related]
2. Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.
Zhan L; Qin Q; Lu J; Liu J; Zhu H; Yang X; Zhang C; Xu L; Liu Z; Cai J; Ma J; Dai S; Tao G; Cheng H; Sun X
Dis Esophagus; 2016 Apr; 29(3):215-23. PubMed ID: 25604309
[TBL] [Abstract][Full Text] [Related]
3. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia.
Liu SK; Coackley C; Krause M; Jalali F; Chan N; Bristow RG
Radiother Oncol; 2008 Aug; 88(2):258-68. PubMed ID: 18456354
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Schaefer NG; James E; Wahl RL
Nucl Med Commun; 2011 Nov; 32(11):1046-51. PubMed ID: 21956491
[TBL] [Abstract][Full Text] [Related]
5. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
6. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
[TBL] [Abstract][Full Text] [Related]
7. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
8. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
9. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV; de Haan R; Hageman F; Oostendorp TP; Carli AL; O'Connor MJ; Jonkers J; Verheij M; van den Brekel MW; Vens C
Radiother Oncol; 2015 Sep; 116(3):358-65. PubMed ID: 25981132
[TBL] [Abstract][Full Text] [Related]
10. The combination of olaparib and camptothecin for effective radiosensitization.
Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice.
Lourenco LM; Jiang Y; Drobnitzky N; Green M; Cahill F; Patel A; Shanneik Y; Moore J; Ryan AJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):767-775. PubMed ID: 29413287
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines.
Waissi W; Amé JC; Mura C; Noël G; Burckel H
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201963
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
15. Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.
de Haan R; Pluim D; van Triest B; van den Heuvel M; Peulen H; van Berlo D; George J; Verheij M; Schellens JHM; Vens C
Radiother Oncol; 2018 Mar; 126(3):443-449. PubMed ID: 29150161
[TBL] [Abstract][Full Text] [Related]
16. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM
Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991
[No Abstract] [Full Text] [Related]
17. Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells.
Rae C; Mairs RJ
Int J Radiat Biol; 2017 Feb; 93(2):194-203. PubMed ID: 27600766
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
[TBL] [Abstract][Full Text] [Related]
19. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
20. PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Michmerhuizen AR; Pesch AM; Moubadder L; Chandler BC; Wilder-Romans K; Cameron M; Olsen E; Thomas DG; Zhang A; Hirsh N; Ritter CL; Liu M; Nyati S; Pierce LJ; Jagsi R; Speers C
Mol Cancer Ther; 2019 Nov; 18(11):2063-2073. PubMed ID: 31413177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]